Skip to main
TVGN

TVGN Stock Forecast & Price Target

TVGN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tevogen Bio Holdings is a promising clinical-stage company with a potential breakthrough therapy, TVGN 489, that targets COVID-19 and its lingering symptoms. With a diversified pipeline of products targeting infectious diseases, cancers, and neurological disorders, and a focus on precision T cell therapies, the company has strong growth potential. However, there are inherent risks in the biotech industry, including clinical and regulatory uncertainty and potential legal and financial challenges, that could impact the success of the company. Nonetheless, with its innovative approach and strong management team, Tevogen Bio Holdings is well-positioned for future success.

Bears say

Tevogen Bio Holdings is facing potential trading pressures due to the upcoming reverse split, creating a temporary vacuum in demand for shares and reducing liquidity in the market. The company's dilution risk and delayed timing of commercialization also contribute to our negative outlook on the stock. Additionally, while the potential acquisition of a Contract Research Organization may offer strategic and financial benefits, there is no guarantee of completion and it remains subject to various conditions.

TVGN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Semper Paratus Acquisition Corp (TVGN) Forecast

Analysts have given TVGN a Strong Buy based on their latest research and market trends.

According to 1 analysts, TVGN has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Semper Paratus Acquisition Corp (TVGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.